NMS 03597812
Alternative Names: NMS-03597812; NMS-812Latest Information Update: 28 Oct 2025
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF-2 kinase inhibitors; EIF2AK4 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Phase I Acute myeloid leukaemia; Multiple myeloma
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (PO)
- 28 Oct 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Monotherapy, Second-line therapy or greater) in USA (PO)
- 28 Aug 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06549790)